Immuneering (NASDAQ:IMRX) Receives “Buy” Rating from Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Immuneering (NASDAQ:IMRX) in a research report report published on Thursday,Benzinga reports. Needham & Company LLC currently has a $15.00 price objective on the stock.

Separately, Chardan Capital lowered their price objective on Immuneering from $16.00 to $12.00 and set a “buy” rating for the company in a research report on Wednesday, August 7th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $12.60.

Immuneering Trading Down 7.0 %

NASDAQ:IMRX traded down $0.14 during trading hours on Thursday, hitting $1.81. 369,671 shares of the company were exchanged, compared to its average volume of 2,260,222. The company has a fifty day simple moving average of $2.15 and a 200 day simple moving average of $1.61. Immuneering has a one year low of $1.00 and a one year high of $8.89. The stock has a market capitalization of $53.52 million, a price-to-earnings ratio of -0.93 and a beta of -0.40.

Institutional Trading of Immuneering

Large investors have recently made changes to their positions in the company. Vontobel Holding Ltd. acquired a new stake in shares of Immuneering in the 3rd quarter valued at about $25,000. Corsair Capital Management L.P. acquired a new stake in shares of Immuneering in the 3rd quarter valued at about $25,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Immuneering in the 2nd quarter valued at about $44,000. XTX Topco Ltd grew its stake in shares of Immuneering by 37.3% in the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock valued at $44,000 after buying an additional 9,274 shares during the period. Finally, Acadian Asset Management LLC acquired a new stake in shares of Immuneering in the 2nd quarter valued at about $67,000. 67.65% of the stock is currently owned by institutional investors and hedge funds.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.